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lthough growth factors have been shown to inﬂuence
mammary gland development, the nature of down-
stream effectors remains elusive. In this study, we
show that the expression of p21-activated kinase (Pak)1, a
serine/threonine protein kinase, is activated in mammary
glands during pregnancy and lactation. By targeting an
ectopic expression of a kinase-dead Pak1 mutant under the
control of ovine 
 
 
 
-lactoglobulin promoter, we found that
the mammary glands of female mice expressing kinase-
dead Pak1 transgene revealed incomplete lobuloalveolar
development and impaired functional differentiation. The
expression of whey acidic protein and 
 
 
 
-casein and the
amount of activated Stat5 in the nuclei of epithelial cells in
A
 
transgenic mice were drastically reduced. Further analysis
of the underlying mechanisms revealed that Pak1 stimulated
 
 
 
-casein promoter activity in normal mouse mammary epi-
thelial cells and also cooperated with Stat5a. Pak1 directly
interacted with and phosphorylated Stat5a at Ser 779, and
both COOH-terminal deletion containing Ser 779 of Stat5a
and the Ser 779 to Ala mutation completely prevented the
ability of Pak1 to stimulate 
 
 
 
-casein promoter. Mammary
glands expressing inactive Pak1 exhibited a reduction of
Stat5a Ser 779 phosphorylation. These ﬁndings suggest that
Pak1 is required for alveolar morphogenesis and lactation
function, and thus, identify novel functions of Pak1 in the
mammary gland development.
 
Introduction
 
Mammary gland development consists of a series of highly
orchestrated events involving interactions among several
distinct cell types that are regulated by complex interactions
among many steroid hormones and growth factors and their
 
receptors (Medina, 1996; Hennighausen et al., 1997; Kumar
and Wang, 2002). Beside steroid hormones and their recep-
tors, peptide growth factors and their receptors are shown to
play important roles in both the morphogenesis and func-
tional differentiation of mammary gland. For example,
among the EGF receptor family receptors, EGF receptor (also
known as HER1) and its ligand amphiregulin have been
shown to be critical for ductal growth (Fowler et al., 1995;
Xie et al., 1997; Luetteke et al., 1999). In contrast, HER2,
HER3, and HER4 play essential roles in the lobuloalveolar
development and functional differentiation (Niemann et al.,
1998; Jones et al., 1999; Jones and Stern, 1999). Heregulin, a
ligand for HER3 and HER4 receptors, is expressed during
pregnancy and early lactation and has been implicated in the
morphogenesis and differentiation of mammary epithelial
cells (Yang et al., 1995; Jones et al., 1996). Though HER3 is
a kinase-dead receptor, its heterodimerization with HER2 is
important for lobuloalveolar morphogenesis (Baeckstrom et
al., 2000). HER4 has been shown to activate Stat5 and pro-
mote alveolar differentiation (Jones et al., 1999).
Stat5 was originally isolated from the nuclear extracts
of lactating mammary gland and designated as mammary
growth factor (Wakao et al., 1992). There are two separately
coded isoforms of Stat5, Stat5a and Stat5b, which are highly
homologous and provide functional redundancy to each other
(Hennighausen and Robinson, 2001). Upon phosphorylation,
Stat5 translocates to the nucleus and activates the expression of
milk proteins such as 
 
 
 
-casein (Hennighausen and Robinson,
2001). Stat5 could be activated by prolactin and its receptor,
and by peptide growth factors and their receptors, e.g., HER4
has also been shown to activate Stat5 (Ruff-Jamison et al.,
1995; David et al., 1996; Olayioye et al., 1999). However, the
signaling pathway connecting growth factors to Stat5a in
mammary epithelium cells remains poorly understood.
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One of the major protein kinases downstream of heregu-
lin and the EGF family of receptors is the p21-activated ki-
nase (Pak)1,* a serine/threonine kinase (Adam et al., 1998).
The Pak1 is an effector of the small GTPases Cdc42 and
Rac1 (Manser et al., 1994; Nicolas and Hall, 1997) and
phosphatidylinositol-3 kinase and mediates the cellular ef-
fects of polypeptide growth factors in breast cancer cells. Re-
cent studies have shown that Pak1 regulates motility, inva-
siveness, anchorage-independent growth, cell survival, and
angiogenesis in human breast cancer cells (Bagrodia and Ce-
rione, 1999; Kumar and Vadlamudi, 2002). Pak1 also mod-
ulates the activation status of MAPK and p38MAPK, and
thus, influences nuclear signaling (Adam et al
 
.,
 
 2000; Vadla-
mudi et al., 2000a). In spite of a large number of studies in
tissue culture model systems, the role of Pak1 signaling in
the normal mammary development in a physiological rele-
vant whole animal setting remains unknown and is investi-
gated in the present study.
 
Results
 
Generation of DN-Pak1 transgenic mice
 
To elucidate the functional significance of the Pak1 signal-
ing pathway in the murine mammary gland development,
we first examined the Pak1 expression and kinase activity
pattern. We found that Pak1 expression is easily detectable
in the mammary glands, with an up-regulation of both pro-
tein level and kinase activity during pregnancy and lactation
(Fig. 1 A). Accordingly, Nck, a Pak1 adaptor protein, fol-
lows the similar pattern of expression. In contrast, Pak2 and
Pak3 expression is not periodically regulated (Fig. 1 A).
Next, we targeted expression of a kinase-defective K299R-
Pak1 mutant protein (Adam et al., 2000) (designated as
dominant-negative (DN)-Pak1) during pregnancy and lacta-
tion by using the ovine 
 
 
 
-lactoglobulin (BLG) promoter
(Lundgren et al.
 
,
 
 1997). In the targeted K299R-Pak1 se-
quence, the lysine 299 ATP-binding site was replaced by
arginine, rendering Pak1 catalytically defective (Sells et al.,
1997). Earlier studies in mammary cancer cell lines have es-
tablished that the biological effects of the K299R-Pak1 in
human mammary epithelial cancer cells can be mimicked
by Pak1 mutant H83, 86L (which has mutations in CRIB
site), and by the Pak1 autoinhibitory domain aa 83–149,
and hence, were not due to ineffective transduction of Rac/
cdc42 signal (Adam et al., 1998, 2000; Bagheri-Yarmand et
al., 2001).
An myc-tagged kinase-dead K299R-Pak1 cDNA was
cloned into the pBJ41 vector under the control of an ovine
BLG promoter (Fig. 1 B). Transgenic mice having a
B6DF1/J genetic background were produced by injection of
purified DNA fragments into the pronucleus of fertilized
mouse oocytes. The F2 and F3 generation mice were used
for phenotype analysis. Among the 39 mice analyzed, we
identified six DN-Pak1-TG founder mice (Fig. 1 C). Ex-
pression of the DN-Pak1 transgene was determined using
RT-PCR by amplifying the region spanning the myc tag and
NH
 
2
 
 terminus of Pak1. As expected, a 345-bp transgene
fragment was found in the transgenic mice but not in the
wild-type mice, and the integrity of PCR band was verified
using Southern blotting (Fig. 1 D, lanes 1 and 2, line 1; lane
3, line 3; lane 4, wild type). Of the six lines of DN-Pak1
transgenic mice, lines 1 and 3 had the highest level of trans-
gene expression and were used in the subsequent analysis.
The kinetics of DN-Pak1 expression in the various stages
of mammary gland development was determined using a
semiquantitative RT-PCR followed by Southern blot hy-
bridization. DN-Pak1 expression began on the tenth day of
pregnancy, peaked around the second day of lactation, and
returned to near the basal level, albeit detectable, at the sev-
enth day after weaning (Fig. 1 E). This profile is in ac-
Figure 1. Pak1 expression and kinase activity in 
murine mammary gland development; generation 
of DN-Pak1 transgenic mice. (A) Expression and 
kinase activity pattern of Pak1 and its related 
molecules during mammary gland development. 
(B) Schematic diagram showing the structure of the 
transgene. BLG, ovine  -lactoglobulin promoter; 
PBD, p21 GTPase-binding domain. (C) Genotyping 
of the founder mice using Southern blotting. The 
tail DNA was digested with BamHI, and a transgene 
fragment was detected via Southern blotting. L1-L6, 
lines 1–6; WT, wild type;  con, positive vector 
control. (D) Transgene expression analysis using 
RT-PCR followed by Southern blotting. Lanes 1–3, 
DN-Pak1-TG mice on lactation day 12; lane 4, 
wild-type mice on lactation day 12; lanes 5–7 are 
from the same mice as lanes 1–3. (E) Quantitation 
of the transgene expression profile during mammary 
gland development. P, pregnancy; L, lactation; 
Pw, postweaning; numbers, days in a particular 
stage. (Insert) Transgene RT-PCR/Southern blotting 
at the representative stages P10 (pregnancy day 10) 
and L5 (lactation day 5). (F) Total lysates of 
mammary glands obtained from lactation day 5 
mammary glands from the wild-type and Pak1-TG 
mice were assayed for Pak1 kinase activity using 
MBP as a substrate.T
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cordance with the previously reported BLG-MDM2 mice
(Lundgren et al
 
.
 
, 1997). As expected, DN-Pak1 expression
inhibited the endogenous Pak1 activity in lactating mam-
mary glands (Fig. 1 F).
 
DN-Pak1 expression impairs morphogenesis 
during pregnancy
 
To determine the effect of Pak1 inactivation on the mor-
phogenesis of the mammary gland, whole-mount and sec-
tion hematoxylin and eosin (H-E) staining were performed.
Normally, during pregnancy the mammary glands grow
quickly and the ducts branch out and form lobules and alve-
oli. On the second day of lactation, the glandular tissues
filled up the fat pad and the epithelial cells fully differenti-
ate. During the virgin and early pregnant stages, the mam-
mary glands of DN-Pak1-TG mice were not obviously dif-
ferent from those of the wild-type mice (unpublished data).
However, at the late stages of pregnancy, the transgenic
mammary glands showed marked dystrophy with fewer visi-
ble branches and poorly developed alveoli compared with
the widespread branches and flourishing alveoli from the
age-matched wild-type mammary glands (Fig. 2). Further-
more, on the 12th day of lactation, although the glandular
tissues filled up the fat pad in the wild-type mammary
glands, the transgenic mammary glands had distinct spaces
in the absence of glandular tissues (Fig. 2, C and F). The
H-E–stained sections also demonstrated poor lobular alveo-
lar development on the 18th day of pregnancy and moderate
dystrophy during lactation (Fig. 3, B, C, E, and F).
To understand the cytological basis of the observed poor
alveolar development in the mammary glands having DN-
Pak1-TG expression, we analyzed the status of cell prolifera-
tion and death during the pregnancy and lactation using
proliferative cell nuclear antigen (PCNA) and TUNEL
staining, respectively. Mammary glands obtained from preg-
nant DN-Pak1-TG mice exhibited a reduced proliferation
rate (P
 
 
 
 
 
 
 
0.05, 
 
n
 
 
 
 
 
 6) and an elevated cell death rate (P
 
 
 
 
 
0.01, 
 
n
 
 
 
 
 
 6) compared with those obtained from age-
matched wild-type mice (Fig. 4. A–C).
 
DN-Pak1-TG mammary glands are less 
functionally differentiated
 
Since the DN-Pak1-TG mice exhibited impaired lobuloal-
veolar development, we explored whether this is accompa-
nied by defective milk production. Indeed, the growth of the
pups from and nursed by DN-Pak1-TG mothers was signif-
icantly retarded compared with those from the wild-type
mothers (Fig. 5, A and B, P
 
 
 
 
 
 
 
0.05). The high level of Pak1
expression and activity during lactation and incomplete
structural differentiation of lactating DN-Pak1-TG mam-
mary glands suggested the possibility of a functional role of
Pak1 in lactation. Therefore, we examined the expression of
two major milk proteins, 
 
 
 
-casein and whey acidic protein
(WAP), by Northern blotting. The levels of both 
 
 
 
-casein
and WAP mRNA were significantly reduced in the mam-
mary glands of DN-Pak1-TG mice compared with those in
the age- and stage-matched wild-type mice (Fig. 5 C). To
further observe that the reduced milk WAP expression in the
Northern analysis was due to total reduction of alveoli epi-
thelium or reduced WAP expression in the functional epi-
Figure 2. Effect of DN-Pak1 expression on mammary gland 
morphogenesis. Whole-mount staining of mammary glands obtained 
from wild-type and DN-Pak1-TG mice during the pregnancy and 
lactation stages. (A and D) In the 15th day of pregnancy, the alveoli 
of DN-Pak1-TG mice are less and smaller than those of wild-type 
mice. (B and E) In the 18th day of pregnancy, the DN-Pak1-TG 
mammary glands show much poorer development than the wild-type 
ones, and the alveoli are few and confined to the periphery of ducts, 
which can be viewed more clearly in Fig. 3 E. (C and F) Lactation 
day 12 mammary glands. Although the wild-type mammary is fully 
developed, DN-Pak1-TG mammary glands still have wide spaces of 
fat pad not filled up. Bar, 40  M.
Figure 3. H-E staining showing the fine histology of the same 
stages depicted in Fig. 2, the wild-type and DN-Pak1-TG glands. 
Bar, 10  M. WT, wild type; numbers, days in a particular stage.T
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thelium, we performed an in situ hybridization assay of
WAP in the lactating mammary glands. Interestingly, we
found a significant suppression of WAP mRNA expression
in lactating mammary glands from DN-Pak1 transgenic
mice compared with mammary glands from the age-
matched wild-type mice (Fig. 5 D).
 
Pak1 stimulates 
 
 
 
-casein promoter in association 
with Stat5a
 
To understand the mechanism of Pak1 regulation of
 
 
 
-casein expression, we next evaluated the effects of various
wild-type or mutant Pak1 on 
 
 
 
-casein promoter activity us-
ing cultured HC11 normal mouse epithelial cells (Marte et
al.
 
,
 
 1995; Vadlamudi et al., 2000b). Interestingly, cotrans-
fection with wild-type Pak1 but not DN-K299R-Pak1 sig-
nificantly enhanced the 
 
 
 
-casein promoter activity in the ab-
sence of exogenous hormones (Fig. 6 A). Furthermore,
cotransfection of HC11 cells with wild-type or catalytically
active T423E-Pak1 (Sells et al., 1997; Vadlamudi et al.,
2000a) resulted in a significant potentiation of stimulation
of the 
 
 
 
-casein promoter activity by lactogenic hormones,
i.e., dexamethasone, insulin, and prolactin (Fig. 6 B; P
 
 
 
 
 
0.001, 
 
n
 
 
 
  
 
6). In contrast, coexpression of K299R-Pak1
mutant effectively blocked the ability of lactogenic hor-
mones to stimulate the 
 
 
 
-casein promoter activity (Fig. 6 B;
P
 
 
 
  
 
0.01, 
 
n
 
 
 
  
 
6).
Earlier studies established a role for nuclear translocation
of the activated transcription factor Stat5
 
Y694-P
 
 in milk pro-
tein gene transcription and differentiation of mammary
gland epithelial cells (Liu et al., 1997; Kazansky et al.,
1999). To see if the DN-Pak1 overexpression induced phe-
notype is related to the functional status of Stat5, we next
determined the status of phosphorylation and expression of
Stat5. Using an anti-Stat5
 
Y694-P
 
 antibody, we detected spe-
cific nuclear Stat5
 
Y694-P
 
 staining in the wild-type mammary
glands (Fig. 7 A), but the staining in DN-Pak1-TG mice
was greatly reduced (Fig. 7 B). Consistent with these find-
ings, mammary gland tissue lysates from DN-Pak1-TG
mice contained a reduced amount of Stat5 and a further re-
duced amount of phosphorylated Stat5 at Y694 (Fig. 7 C).
Figure 4. Pak1 inactivation promotes apoptosis 
and slows down proliferation in pregnant mammary 
glands. (A and B) TUNEL staining of mammary 
glands obtained from wild-type and transgenic mice 
at the 15th day. (C) Quantitation of the TUNEL-
positive apoptotic cells in mammary glands of 
15th and 18th day of pregnancy. **P   0.01. 
(D and E) Immunohistochemical staining of PCNA in 
15th day pregnant mammary glands to evaluate cell 
proliferation rate. (F) Quantitation of PCNA-positive 
cells. *P   0.05.
Figure 5. Expression of DN-Pak1 impairs milking 
function. (A) Pups at the age of 15 d. The pups nursed 
by a transgenic mother were much smaller than that 
nursed by a wild-type mother (labeled with an asterisk). 
(B) Average body weights (in grams) of pups from lines 
1 and 3 and of wild-type mothers at the age of 15 d. 
Bar, mean   SD. (P   0.01, n   24 each group from 
three litters. Each liter was standardized to 8 pups. 
(C) Northern blots analysis of the  -casein and WAP 
expression in three of 3-mo-old, lactation day 12 
mammary glands from DN-Pak1 transgenic and 
wild-type mice. (D) In situ hybridization using the 
12th day lactation mammary glands for WAP; sense 
probe was used as specificity control.T
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We next wanted to delineate the signaling mechanism
linking Pak1 to Stat5. We observed that a dominant-nega-
tive mutant of Stat5a with a deletion of 99 aa at the
COOH-terminal (Mui et al., 1996) drastically decreased the
ability of Pak1 stimulation of 
 
 
 
-casein promoter-driven
transcription (Fig. 8 A, P 
 
 
 
 
 
0.01, 
 
n
 
 
 
  
 
6), suggesting that
Stat5 is important for Pak1-mediated 
 
 
 
-casein transcription.
Although Tyr-694 phosphorylation of Stat5 is markedly re-
duced in our DN-Pak1-TG mice, it is not a Pak1 phosphor-
ylation site and could not be the direct target of Pak1. Since
Pak1 activates both the p38-MAPK and p42/44 MAPK
(Vadlamudi et al., 2000a), we determined the effects of in-
hibiting these signaling kinases by DN p38MAPK and DN
MEK, which blocks MAPK activity (Liu et al., 2001), on
Pak1 induced 
 
 
 
-casein transactivation. The results showed
there was not any inhibitory effect (Fig. 8 B), suggesting a
lack of involvement of these two signaling kinases in the no-
ticed Pak1 regulation of 
 
 
 
-casein promoter activity. Interest-
ingly, catalytically active T423E-Pak1 mutant drastically
stimulated 
 
 
 
-casein promoter when cotransfected with wild-
 
type Stat5a in the absence of lactogenic hormones (Fig. 8
C). These findings raised the possibility that Pak1 may di-
rectly phosphorylate Stat5a.
 
Pak1 interacts with and phosphorylates Stat5a
 
To implicate a role of Pak1 signaling in Stat5a activation,
we first examined if Pak1 interacts with Stat5a in GST pull-
down assay using 
 
35
 
S-labeled Pak1 and purified GST–Stat5a
fusion protein. Results show that GST–Stat5a but not GST
alone interacted with Pak1 (Fig. 9 A). Since Stat5a is consti-
tutively phosphorylated at the Ser 779 (S
 
779
 
) site, and the
levels of Stat5a–Ser 779 phosphorylation are specifically
high in late pregnancy and early lactation, and because the
kinase, which phosphorylates this site, is unknown (Beuvink
et al., 2000), we hypothesized that Pak1 may represent a po-
tential kinase for Ser 779 phosphorylation of Stat5a. A care-
ful examination of Stat5a structure suggested that, indeed,
Stat5a Ser 779 could serve a Pak1 consensus site. The phos-
phorylation site of Stat5a Ser 779 has sequence of ARLS
containing one basic charge in -3 similar to some of the
Figure 6. Pak1 up-regulates  -casein promoter 
activity. (A) Wild-type Pak1 but not K299R Pak1 
stimulates  -casein promoter. HC11 cells were 
cotransfected with  -casein promoter luciferase, 
 -galactosidase, and indicated Pak1 constructs. The 
results are presented as normalized luciferase activity 
(***P   0.001). The experiments are repeated three 
times. (B) Pak1 modulates the up-regulation of  -casein 
promoter activity by hormones. HC11 cells were 
cotransfected with  -casein promoter luciferase, 
 -galactosidase, and the indicated Pak1 constructs. Cells 
were then treated with a mixture of dexamethasone, 
insulin, and prolactin (DIP) for 16 h. The results are 
presented as normalized luciferase activity (**P   0.01; 
***P   0.001). Each experiment was repeated three 
times.
Figure 7. DN-Pak1-TG mammary glands show 
decreased Stat5 tyrosine phosphorylation and 
expression. (A and B) Immunohistochemical staining 
of phospho-Stat5a in mammary glands obtained from 
wild-type and Pak1-TG mice on lactation day 5. 
(C) Effect of Pak1 inactivation on the levels of Stat5a 
and phosphorylated Stat5a by immunoblot analysis. 
Bar: (A and B) 20  m.T
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other Pak phosphorylation sites found in MEK1 and Vi-
mentin. Thus, we next tested whether Stat5a is a substrate
of Pak1. Results show that Pak1 enzyme directly phosphor-
ylates Stat5a (Fig. 9 B). Interestingly, Pak1-mediated phos-
phorylation of Stat5a was also readily detected with an anti-
body (Beuvink et al., 2000) that specifically recognizes
phosphorylated Stat5a on Ser 779 (Fig. 9 C). To validate
that Ser 779 on Stat5a was a bona fide Pak1 phosphoryla-
tion site, we next used the Stat5a mutant with Ser 779 to
Ala (S779A) substitution. As we expected, Pak1 failed to
Figure 8. Pak1 stimulates the  -casein promoter activity by interacting with Stat5a. HC11 cells were cotransfected with  -casein promoter 
luciferase and the indicated constructs, treated with or without lactogenic hormones. (A) Pak1 stimulates  -casein promoter activity when 
cotransfected with wild-type Stat5a, but this stimulation is almost gone when cotransfected with mutated Stat5a, which has a COOH-terminal 
deletion including the site of Ser 779. (B) Pak1 stimulation of  -casein promoter cannot be blocked by the dominant-negative forms of 
p38MAPK or MEK. (C) Constitutive active T423E-Pak1 strongly stimulates  -casein promoter when cotransfected with wild-type Stat5a 
without DIP treatment. *P   0.05; **P   0.01; ***P   0.001; ns, P   0.05, not significantly different.
Figure 9. Pak1 directly interacts 
and phosphorylates Stat5a in vitro. 
(A) 
35S-labeled Pak1 TNT products were 
pulled down by GST–Stat5a but not 
GST alone. (B) GST–Stat5a protein was 
incubated with Pak1 at the presence of 
[ -
32P]ATP and resolved on an SDS-PAGE 
gel. A clear band at the size of GST–Stat5a 
showed up by autoradiography (panel 1), 
and the same band is also recognized by 
blotting with Ser 779–phospho–specific 
Stat5a antibody (panel 3). (C) The 
experiment was done the same way 
as in B, but the phospho-Stat5a band 
cannot be detected with the S779A 
mutant GST–Stat5a. (D and E) HC11 
cells were transfected with indicated 
expression constructs, and treated with 
or without DIP, serum starved, and 
labeled with 
32P-orthophosphate 
overnight. Cells were lysed, immuno-
precipitated with HA antibodies, and 
resolved on SDS-PAGE developed by 
autoradiography. The same cell lysates 
were also checked for the expression of 
transfected plasmids by direct Western 
blotting. (F) Phosphorylation status of 
Stat5a
S779 in different developmental 
stages of wild-type versus DN-Pak1-TG 
mammary glands. Western blotting was 
done with anti-Stat5a
S779 in the presence 
of nonphospho absorption peptide 
(Beuvink et al., 2000) and antibodies 
against total Stat5a. The ratio of Stat5a
S779 
was normalized with the virgin stage as 1.T
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phosphorylate the S779A-Stat5a mutant (Fig. 9 C). Since
Stat5b lacks the Ser 779 site, as an additional control, the
Pak1 enzyme failed to phosphorylate Stat 5b (Fig. 9 D),
suggesting that Pak1 specifically phosphorylates the Ser 779
site in Stat5a.
To examine the effect of Pak1 phosphorylation on Stat5a
in vivo, HC11 cells were cotransfected with Pak1 and/or
Pak1 inhibitory fragment aa 83–149 (Bagheri-Yarmand et
al., 2001), wild-type or mutant HA-tagged Stat5a, treated
with or without dexamethasone, insulin, and prolactin
(DIP), and cells were metabolically labeled with 
32P-ortho-
phosphoric acid. Cell lysates were immunoprecipitated with
an anti-HA mAb and analyzed by autoradiography. Results
indicated that transfected Stat5a was phosphorylated in re-
sponse to DIP treatment, and this phosphorylation could be
blocked by the expression of Pak1 aa 83–149 inhibitory
fragment (Fig. 9 E). Further experiments showed that Stat5a
phosphorylation was also blocked by both K299R Pak1 and
S779A Stat5a mutant (Fig. 9 F). These results further vali-
date the physiological significance of Pak1 phosphorylation
of Stat5a at Ser 779.
Pak1 stimulates  -casein promoter activity through phos-
phorylation of Stat5a at Ser 779 with the establishment of Ser
779 of Stat5a as the major phosphorylation site by Pak1. We
next evaluated if mutation of this site will also block Pak1-
mediated stimulation of  -casein promoter activity similar to
the inhibition obtained by a truncated Stat5a mutant in Fig.
8 A. Not surprisingly, S779A mutation of Stat5a also totally
blocked the Pak1 stimulation of  -casein promoter activity
with or without DIP treatment (Fig. 10, A and B).
Discussion
By using a DN-Pak1 mutant under the control of ovine
BLG promoter, which is expressed during pregnancy and
lactation, we have shown that targeted inactivation of Pak1
in mammary epithelial cells leads to severe impairment of
normal development of mammary glands. In particular,
Pak1 signaling is required for lobuloalveolar development
and lactation functions during mammary gland morphogen-
esis. At least one of the underlying mechanisms includes
Pak1-mediated direct phosphorylation of the Ser 779 site
of Stat5a transcription factor, leading to stimulation of
 -casein promoter activity.
Mammary gland development can be divided into phases
of ductal development and lobuloalveolar development.
Ductal development is achieved after puberty without preg-
nancy. Usually, in 12-wk-old virgin mice ductal branches fill
the whole mammary pad. And the lobuloalveolar develop-
ment is dependent on pregnancy and requires pregnancy-
linked signals. Among a bunch of signals, prolactin-Jak2-
Stat 5 pathways are believed to play key roles in alveolar de-
velopment and differentiation. Null mutation of any one of
these three molecules has been found to result in almost
complete loss of alveolar development (Miyoshi et al., 2001;
Shillingford et al., 2002). However, several other molecules,
including growth factors and protein kinases, are also up-
regulated during pregnancy and lactation and have been
shown to be involved in alveolar development or milking
(Chodosh et al., 2000). For example, Stat5 cannot only be
activated through the prolactin receptor but also by growth
hormones and EGF receptors in mammary epithelia (Gal-
lego et al., 2001). Moreover, the prolactin receptor also
stimulates phosphatidylinositol 3-kinase pathway, a known
upstream activator of Pak1 signaling (Adam et al., 1998).
Pak1-mediated signal in alveolar development may not be
related to the phosphorylation of Stat5a, since the null mu-
tation of Stat5a did not display a defect in alveolar develop-
ment but rather in the functional differentiation (Liu et al.,
1997). The mechanism of Pak1 regulation of the alveolar
morphogenesis might involve its role in supporting cell sur-
vival (Schurmann et al., 2000) and promoting cell prolifera-
tion (Howe and Juliano, 2000; Vadlamudi et al., 2000a),
since we noticed an increased apoptosis and a decreased pro-
liferation rate of epithelial cells in the pregnant DN-Pak1-
TG mammary glands.
We also considered the possibility of whether Pak1 inhibi-
tion-associated disruption of the cytoskeleton might con-
tribute to the noticed phenotypes. However, our data does
not support this possibility, since there was no significant
difference in the status of actin staining in mammary glands
from transgenic and wild-type mice (Fig. S1, available at
http://www.jcb.org/content/full/jcb.200212066/DC1). It is
possible that the lack of effect of Pak1 on cytoskeletal reor-
Figure 10. Pak1 stimulates the  -casein 
promoter activity by phosphorylating 
Stat5a at the Ser 779 site. HC11 cells 
were cotransfected with  -casein 
promoter luciferase and the indicated 
constructs, treated with or without 
lactogenic hormones. (A) Pak1-stimulated 
 -casein promoter was blocked by the 
S779A mutation of Stat5a. (B) The S779A 
mutant responded to lactogenic hormone 
treatment equally as wild-type Stat5a in 
stimulating  -casein promoter activity, 
but Pak1 cannot further increase it 
as to wild-type Stat5a. **P   0.01; 
***P   0.001; ns, P   0.05, not 
significantly different.T
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ganization in the transgenic mice could be due to the fact
that Pak1 affects cytoskeleton via kinase-dependent and -in-
dependent functions (Sells et al., 1997; Adam et al., 2000;
Vadlamudi et al., 2000a). Kinase-dependent functions are
implicated in dissolution of stress fibers, whereas kinase-
independent functions are implicated in generation of
lamellipodia and ruffling via protein–protein interactions. In
addition, Pak2 and Pak3 whose kinase domain is highly
conserved to Pak1 is highly expressed in mammary gland
and may compensate the Pak1 kinase activity, which is re-
quired for reorganization of cytoskeleton.
Stat5a was originally isolated from pregnant mammary
gland (Wakao et al., 1992), named mammary gland
growth factor, and is shown to play a role in the normal
morphogenesis of mammary gland by supporting cell sur-
vival and stimulating epithelial cell proliferation. Indeed,
the Stat5a-null mutation in mice on a large scale blocked
the alveolar development of mammary gland during preg-
nancy, with a marked reduction in cell proliferation index
of alveolar cells. Therefore, a full functional activation of
Stat5a might be required for the normal mammary gland
development. In brief, our findings of a close phenotypic
resemblance between DN-Pak1-TG mutant Stat5a mice
and that of Pak1 phosphorylated Stat 5a, reduction in the
Stat5a phosphorylation in Pak1 mutant mice, and Pak1
regulation of transcriptional functions of Stat 5a strongly
suggest that Pak1 regulates Stat5a pathway, and in princi-
ple, Stat 5a might act as a downstream target of upstream
activators of Pak1. Therefore, Pak1 regulation of Stat5a
might play a role in morphogenesis and differentiation of
the mouse mammary gland.
The process of mammary gland differentiation is pro-
foundly influenced by Stat5 transactivation functions (Hen-
nighausen et al., 1997). Tyrosine phosphorylation of Stat5,
both a/b isoforms at siteY694/699, is critical for the milk-
ing function of mammary epithelia. In the present study,
the inability of transgenic lactating DN-Pak1-TG mice to
nurse pups is partly due to the impaired alveolar develop-
ment. However, drastic reduction in  -casein and WAP
expression indicated an impairment of the functional
differentiation of existing alveolar epithelia. In fact, the
morphology of DN-Pak1-TG mammary alveoli was dis-
tinctly less differentiated with a reduced level of Stat5 ex-
pression and its phosphorylation at Y694/699. Our data
from normal mammary epithelial HC11 cells also sug-
gested that Pak1 stimulates  -casein promoter activity
in a lactating hormone-independent manner. Moreover,
K299R Pak1 blocks the basal  -casein promoter activity,
highlighting the significance of Pak1 activity in the func-
tions of mammary glands. Immunohistochemical staining
and Western blotting showed that DN-Pak1-TG mam-
mary glands exhibited both reduced expression and de-
creased tyrosine phosphorylation of Stat5. Although these
data help us understand the impairment of mammary
gland functions, the mechanism of this regulation is still
yet to be determined.
Aside from tyrosine phosphorylation, Stat5 is also phos-
phorylated on two other serine sites, Ser 725 (Stat5a)/Ser
730 (Stat5b) and Ser 779, which only exist in Stat5a (Ya-
mashita et al., 1998, 2001; Beuvink et al., 2000); however,
the kinase which phosphorylates these two sites are not
known to date. Here we provided evidence that Pak1 di-
rectly interacts and phosphorylates Stat5a at Ser 779. We
also demonstrated that mutation of Ser 779 to Ala blocks
the ability of Pak1 to phosphorylate Stat5a, and conse-
quently, stimulation of  -casein promoter activity in physi-
ological relevant murine normal mammary epithelial HC11
cells. These findings are significant, sine earlier studies us-
ing COS or MCF-7 cells did not notice any inhibitory ef-
fect of Stat5a Ser 779 Ala on the stimulation of  -casein
promoter activity by prolactin (Beuvink et al., 2000; Ya-
mashita et al., 2001). It is also possible that prolactin signal-
ing does not target Ser 779 phosphorylation, since prolactin
is not an effective inducer of Pak1 activity in HC11 cells
(unpublished data). In summary, results presented here
have shown a role of Pak1 signaling in the Stat5a Ser 779
phosphorylation and transactivation of  -casein promoter
and have shown that targeted inactivation of Pak1 in mam-
mary epithelial cells leads to severe impairment of normal
mammary gland development.
Materials and methods
Transgenic mice and genotyping
An myc-tagged kinase-dead Pak1 cDNA containing lysine to arginine re-
placement at position 299 (K299R) (Sells et al., 1997) was cloned into the
pBJ41 vector under the control of an ovine BLG promoter (Lundgren et al.,
1997) at the site of BamHI. Digestion with Fsp1 released an 8.5-kb frag-
ment from the vector. The fragment was purified on a 0.8% low melting
agarose gel by cutting out the transgenic fragment and digesting it with
GEKase. The DNA was then purified by Resource Q anion exchange FPLC,
and ethanol was precipitated. The fragment was resuspended in 10 mM
Tris (pH 7.4) and 0.1 mM EDTA at a final concentration of 3 ng/ l. The
construct was injected into the pronucleus of fertilized B6DF1/J mouse oo-
cytes and transferred back to pseudopregnant mice uterus (injection and
oocytes transfer were done by Chad Smith [Transgenic Core Facility of
M.D. Anderson Cancer Center]). The founder mice were genotyped via
Southern blotting with 5  g of tail DNA digested with BamHI. The size of
the transgene band is 2.0 kb. PCR genotyping was performed to amplify a
345-bp sequence between the myc tag and Pak1 cDNA using the follow-
ing primers: forward, 5 -CATCTCTGAAGAGGATCTTGTCTAGCG-3  and
reverse, 5 -GGGTTTTTCTTCTGCTCCGACTTA-3 .
Whole-mount and H-E staining
The whole left no. 4 mammary gland of each animal was removed and
mounted on slides. After drying for 10–30 min, the tissues were fixed with
acetic acid/ethanol (1:3) for 1 h. Then, the tissues were rinsed with water
briefly and stained with 0.2% carmine/0.5% aluminum potassium sulfate
overnight. Tissues were then dehydrated through graded ethanol, defatted
through acetone, cleared, and preserved in methyl salicylate. The right no.
4 mammary glands were fixed with 10% formaldehyde, processed to par-
affin sections, and stained with H-E.
Kinase assay
Pak1 assay was performed as reported previously (Adam et al., 1998). 1
mg of total protein lysate was immunoprecipitated with an anti-Pak1 anti-
body (sc-882; Santa Cruz Biotechnology, Inc.) and subjected to an in vitro
complex kinase assay using myelin basic protein as a substrate for 30 min
at 30 C. The reaction products were resolved on a 10% SDS-PAGE gel and
transferred to nitrocellulose membrane. The membrane was exposed to a
phosphoscreen overnight and scanned with Storm PhosphorImager.
Immunohistochemistry and TUNEL staining
Immunohistochemical staining of PCNA (P8825; Sigma-Aldrich), Y
694-
phospho-Stat5 (1:50; 71–6900; Zymed Laboratories) was done with the in-
direct enzyme labeling method as described previously (Wang et al.,
1998). Antigen retrieval was performed by boiling the sections for 10 min
and gradually cooling them down for 30 min in 0.01 M, pH 6.0, citrate
buffer before incubating with the antibody. TUNEL staining was also per-
formed as described previously (Wang et al., 1998).T
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RT-PCR, Northern blot, and immunoblotting
RT-PCR was performed using the Access RT-PCR system (Promega) per the
manufacturer’s instructions. Before performing RT-PCR, the total RNA was
first digested with Q1 DNase for 10 min to get rid of possible genomic
DNA contamination. For Northern blot analysis, 20  g of total RNA was
resolved on a 1% formaldehyde agarose gel, transferred to a nylon mem-
brane, and probed with appropriate probes and exposed to phospho-
screen. For immunoblot analysis, 200  g of the total protein lysate was re-
solved on a 10% SDS–polyacrylamide gel, transferred to nitrocellulose
membrane, and probed with appropriate antibodies.
Expression vectors
Wild-type Pak1, K299R-Pak1 and T423E-Pak1 (Adam et al., 1998), and
GST–S779A-Stat5a (Beuvink et al., 2000) plasmids have been described
previously.  -casein promoter-luciferase vector was obtained from Dr. J.
Rosen (Baylor College of Medicine, Houston, TX), DNp38-MAPK was from
Dr. S. Ludwig (University of Wurzburg, Wurzburg, Germany).
Cell culture, transfection, and luciferase assay
HC11 mouse epithelial cells were maintained in RPMI-1640 medium sup-
plemented with 8% FCS, 10 ng EGF/ml, and 5  g insulin/ml as described
previously (Vadlamudi et al., 2000b). Cells were plated in six-well culture
plates, and transfection was performed using the Fugene (Roche) method.
Luciferase assay was performed according to the manufacturer’s instruc-
tions as described previously (Mazumdar et al., 2001) and results were
standardized against  -gal luciferase of internal control. Each experimental
group includes three triplicate plates.
GST pull-down assays
In vitro transcription and translation of the Pak1 were performed using the
TNT transcription–translation system (Promega) as described (Mazumdar
et al., 2001). In brief, the appropriate cDNAs (1  g) were translated in vitro
in the presence of 
35S-methionine in a reaction volume of 50  l using a T7-
TNT kit (Promega). The reaction mixture was diluted to 1 ml with NP-40
lysis buffer (25 mM Tris, 50 mM NaCl, 1% Nonidet P40). A 250-liter ali-
quot was used for each GST pull-down assay. Translation and product size
were verified by analyzing 2  l of the reaction mixture with SDS-PAGE
and autoradiography. GST pull-down assays were performed by incubat-
ing equal amounts of GST and GST immobilized on GST beads (Amer-
sham Biosciences) with in vitro–translated 
35S-labeled Pak1. After incubat-
ing for 2 h at 4 C, the beads were washed five times with NP-40 lysis
buffer, eluted with 2  SDS buffer, and resolved on SDS-PAGE and re-
vealed by autoradiography.
In vitro and in vivo phosphorylation assays
In vitro and in vivo phosphorylation assay was done as described previ-
ously (Vadlamudi et al., 2002). Briefly, for in vitro assay the GST–Stat5a
fusion protein was incubated in 50 mM Hepes, 10 mM MgCl2, 2 mM
MnCl2, and 1 mM dithiothreitol containing 1  g of purified bacterially ex-
pressed GST–Pak1 enzyme, 10  Ci of [ -
32P]ATP and 25 M cold ATP. The
reaction was performed in a volume of 30  l for 30 min at 30 C and then
stopped by adding 10  g of 4  SDS sample buffer, resolved on SDS-PAGE
gel, and revealed by autoradiography. For in vivo phosphorylation assay,
HC 11 cells were transfected with wild-type or S779A mutant Stat5a, wild-
type Pak1 or Pak1 83–149 inhibitory peptide, or K299R Pak1. After 36 h,
the cells were labeled with 
32P-orthophosphate overnight (0.2 mci/ml) and
treated with DIP for 30 min. Cells were lysed, and equal amounts of the
protein were immunoprecipitated with an antibody specific for HA tag to
immunoprecipitate HA-STAT or HA S779A Stat. An aliquot of total lysate
was run as a separate gene gel to analyze the expression of GST–Pak in-
hibitory fragment aa 83–149 and myc-tagged Pak constructs.
In situ hybridization
In situ hybridization was done as we described previously (Wang et al.,
2002). Mouse mammary glands were fixed with 4% PFA, and frozen sec-
tions were cut. A 419 bp of mouse WAP cDNA was amplified by RT-PCR,
subcloned into TOPO II vector (In Vitrogen), and used for riboprobe syn-
thesis under the control of T7 promoter. Primers used are forward, 5 -CCT-
GACACCGGTACCATGCGTTGC-3  and reverse, 5 -CACTGAAGGGT-
TATCACTGGCACT-3 ; RNA probes were labeled with digoxigenin
(Roche) and hybridized for 16–20 h in buffer containing 0.1  g/ml ribo-
probes, 50% formamide, 300 mM NaCl, 10 mM Tris (pH 7.4), 10 mM
NaH2PO4 (pH 6.8), 5 mM EDTA (pH 8.0), 0.2% Ficoll 400, 0.2% polyvinyl
pyrolidone, 10% dextran sulfate, 200  g/ml yeast total RNA, and 50 mM
dithiothreitol. Alkaline phosphatase-labeled sheep antidigoxigenin anti-
body was applied, and signals were visualized by NBT-BCIP. Hybridiza-
tion with sense probe was used as background control.
Quantitation and statistical analysis
Counting of PCNA and TUNEL-positive cells was done manually on the
computer screen for five fields of each case. Statistical analysis for pups
weight, and PCNA and TUNEL staining and  -casein promoter luciferase
assay were done by Student’s t test. Semiquantitation of Western blotting
was performed by using the SigmaGel software.
Online supplemental material
Fig. S1 showing phalloidin staining of actin in mammary glands from wild-
type and DN-Pak1-TG mice is available at http://www.jcb.org/content/full/
jcb.200212066/DC1.
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